{"id":24749,"date":"2023-11-05T04:26:00","date_gmt":"2023-11-04T20:26:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=24749"},"modified":"2023-11-05T20:18:15","modified_gmt":"2023-11-05T12:18:15","slug":"nejm%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e5%a4%b4%e5%ad%a2%e5%90%a1%e6%99%ae%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82%e6%80%a7%e9%87%91%e9%bb%84%e8%89%b2%e8%91%a1%e8%90%84%e7%90%83%e8%8f%8c","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=24749","title":{"rendered":"[NEJM\u53d1\u8868\u8bba\u6587]\uff1a\u5934\u5b62\u5421\u666e\u6cbb\u7597\u590d\u6742\u6027\u91d1\u9ec4\u8272\u8461\u8404\u7403\u83cc\u83cc\u8840\u75c7"},"content":{"rendered":"\n

ORIGINAL ARTICLE<\/a><\/p>\n\n\n\n

Ceftobiprole for Treatment of Complicated Staphylococcus aureus<\/em> Bacteremia<\/h1>\n\n\n\n

Thomas L. Holland, Sara E. Cosgrove, Sarah B. Doernberg, et al<\/h3>\n\n\n\n

N Engl J Med September 27, 2023
DOI: 10.1056\/NEJMoa2300220<\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

BACKGROUND<\/h2>\n\n\n\n

Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus<\/em>bacteremia, including methicillin-resistant S. aureus<\/em>.<\/p>\n\n\n\n

METHODS<\/h2>\n\n\n\n

In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus<\/em>bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new S. aureus<\/em>bacteremia\u2013related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments. Safety was also assessed.<\/p>\n\n\n\n

RESULTS<\/h2>\n\n\n\n

Of 390 patients who underwent randomization, 387 (189 in the ceftobiprole group and 198 in the daptomycin group) had confirmed\u00a0S. aureus<\/em>\u00a0bacteremia and received ceftobiprole or daptomycin (modified intention-to-treat population). A total of 132 of 189 patients (69.8%) in the ceftobiprole group and 136 of 198 patients (68.7%) in the daptomycin group had overall treatment success (adjusted difference, 2.0 percentage points; 95% confidence interval [CI], \u22127.1 to 11.1). Findings appeared to be consistent between the ceftobiprole and daptomycin groups in key subgroups and with respect to secondary outcomes, including mortality (9.0% and 9.1%, respectively; 95% CI, \u22126.2 to 5.2) and the percentage of patients with microbiologic eradication (82.0% and 77.3%; 95% CI, \u22122.9 to 13.0). Adverse events were reported in 121 of 191 patients (63.4%) who received ceftobiprole and 117 of 198 patients (59.1%) who received daptomycin; serious adverse events were reported in 36 patients (18.8%) and 45 patients (22.7%), respectively. Gastrointestinal adverse events (primarily mild nausea) were more frequent with ceftobiprole.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

CONCLUSIONS<\/h2>\n\n\n\n

Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated S. aureus<\/em> bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733. opens in new tab<\/a>.)<\/p>\n","protected":false},"excerpt":{"rendered":"

ORIGINAL ARTICLE Ceftobiprole for Treatment of Complica […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24749"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24749"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24749\/revisions"}],"predecessor-version":[{"id":24850,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24749\/revisions\/24850"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}